DelveInsight’s, “Obstructive Sleep Apnea Pipeline Insight 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Obstructive Sleep Apnea pipeline landscape. It covers the Obstructive Sleep Apnea pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obstructive Sleep Apnea pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Obstructive Sleep Apnea Pipeline Report
- DelveInsight’s Obstructive Sleep Apnea pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Obstructive Sleep Apnea treatment.
- The leading companies working in the Obstructive Sleep Apnea Market include Apnimed, Therapix Biosciences, Eisai, Idorsia Pharmaceuticals, Takeda, Merck & Co, Taisho Pharmaceutical Co., Ltd., Bayer, Janssen Pharmaceuticals, RespireRx Pharmaceuticals, Cortex Pharmaceuticals, Michael James Enterprises, and others.
- Promising Obstructive Sleep Apnea Pipeline Therapies in the various stages of development include AL539 (SRETT), Lemborexant 10 mg, Sulthiame, Eszopiclone, AD182, AD504, Atomoxetine, and others.
- December 2023: Nyxoah S.A., A multicenter study to assess the safety and effectiveness of the Genio dual-sided hypoglossal nerve stimulation system for the treatment of obstructive sleep apnea in adults subjects.
- December 2023: University of Calgary, The primary objective of this study is to evaluate the effect of more timely care for obstructive sleep apnea (OSA) on adherence to positive airway pressure (PAP) therapy at three months after treatment initiation. The secondary objectives are to determine if earlier care improves the treatment effect of PAP on patient reported sleepiness, quality of life and patient satisfaction. We will also evaluate the impact of shorter wait times on patient engagement in therapy by assessing initial acceptance of PAP therapy, patient activation and self-efficacy with respect to OSA treatment.
Request a sample and discover the recent advances in Obstructive Sleep Apnea Treatment Drugs @ Obstructive Sleep Apnea Pipeline Outlook Report
In the Obstructive Sleep Apnea Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Obstructive Sleep Apnea NDA approvals (if any), and product development activities comprising the technology, Obstructive Sleep Apnea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Obstructive Sleep Apnea Overview
Obstructive sleep apnea (OSA) is characterized by episodes of breathing cessation or shallow breathing in sleep. These episodes are due to complete or partial collapse of upper airway. Most of the time, the respiratory events are associated with snoring, oxygen desaturations and brief arousal from sleep.
Find out more about Obstructive Sleep Apnea Therapeutics Assessment @ Obstructive Sleep Apnea Preclinical and Discovery Stage Products
Obstructive Sleep Apnea Emerging Drugs Profile
- Lemborexant : Eisai
- Sulthiame : Desitin Arzneimittel GmbH
- AD 182 : Apnimed
- TAK-925 : Takeda
Obstructive Sleep Apnea Pipeline Therapeutics Assessment
There are approx. 20+ Obstructive Sleep Apnea companies which are developing the Obstructive Sleep Apnea therapies. The Obstructive Sleep Apnea companies which have their Obstructive Sleep Apnea drug candidates in the most advanced stage, i.e. phase II include, Desitin Arzneimittel GmbH.
Obstructive Sleep Apnea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Learn more about the emerging Obstructive Sleep Apnea Pipeline Therapies @ Obstructive Sleep Apnea Clinical Trials Assessment
Obstructive Sleep Apnea Pipeline Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Scope of the Obstructive Sleep Apnea Pipeline Report
- Coverage- Global
- Obstructive Sleep Apnea Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Obstructive Sleep Apnea Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Obstructive Sleep Apnea Companies- Apnimed, Therapix Biosciences, Eisai, Idorsia Pharmaceuticals, Takeda, Merck & Co, Taisho Pharmaceutical Co., Ltd., Bayer, Janssen Pharmaceuticals, RespireRx Pharmaceuticals, Cortex Pharmaceuticals, Michael James Enterprises, and others.
- Obstructive Sleep Apnea Pipeline Therapies- AL539 (SRETT), Lemborexant 10 mg, Sulthiame, Eszopiclone, AD182, AD504, Atomoxetine, and others.
Dive deep into rich insights for new drugs for Obstructive Sleep Apnea Treatment, Visit @ Obstructive Sleep Apnea Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Obstructive Sleep Apnea: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Obstructive Sleep Apnea– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug name : Company name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Sulthiame : Desitin Arzneimittel GmbH
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name : Company name
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name : Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Obstructive Sleep Apnea Key Companies
- Obstructive Sleep Apnea Key Products
- Obstructive Sleep Apnea- Unmet Needs
- Obstructive Sleep Apnea- Market Drivers and Barriers
- Obstructive Sleep Apnea- Future Perspectives and Conclusion
- Obstructive Sleep Apnea Analyst Views
- Obstructive Sleep Apnea Key Companies
- Appendix
For further information on the Obstructive Sleep Apnea Pipeline therapeutics, reach out to Obstructive Sleep Apnea Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services